Sanitize the rubber stopper with a 70% isopropyl alcohol wipe
[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity
The pharmaceutical company added that gallstones and gallbladder infections are uncommon when the drugs are used to manage type 2 diabetes, and may impact one in 100 people
was supported by a Wellcome Trust Clinical Research Training Fellowship
Once the patient has reached their goal weight, oral semaglutide dosage may change as the patient transitions from active weight loss to weight management
